HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US Cannabis Legalization Cultivated By House Has Thorny Forecast For Harvest In Senate

Senate Democrats Want Language For Make Lawful Use Of Hemp Ingredients In Supplements

Executive Summary

Absence of hemp provisions in House bill could be a problem with Senate Democrats, who have drafted legislation not only on producing, marketing and possessing marijuana but also using in supplements ingredients classified as hemp. Still, Senate passage of cannabis legalization is unlikely.

You may also be interested in...

Senate Cannabis Bill Could Torch US Hemp Market By Slashing THC Limit Below Farm Bill Level

Hemp Roundtable says Cannabis Administration and Opportunity Act’s limit of 0.001% THC per 100 g by dry weight for ingredients derived from cannabis to qualify as hemp “would impose a devastating setback to a thriving industry, and further limit opportunities for already struggling hemp farmers.”

CBD Could Be Only Hemp Allowed For Use In Supplements In US, House Appropriators Suggest

Appropriators’ comments provided with FY2023 FDA budget bill suggests agency will resolve dilemma of sales of hemp ingredients in non-drug products by making only CBD lawful.

As US Hemp Product Industry Grows Without Regulatory Clearance, It Has Grown In Compliance

“For companies like Joy Organics, we view it as an advantage that CBD is not currently regulated as a dietary supplement,” says COO Todd Smith. Advantage is borne from hemp ingredient supplements not becoming commoditized, keeping prices from falling. Meanwhile, industry’s maturity can be seen in compliance with FDA rules.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts